

# Trial Design

Multicenter, phase IV,  
randomized clinical trial



## INCLUSION

- Patients aged  $\geq 18$  years
- Hospitalized with a confirmed diagnosis of COVID-19
- Chronic use of ACEI or ARB

**RANDOMIZE**  
N: 659 patients

## EXCLUSION

- Hospitalization due to decompensated heart failure in the last 12 months
- Use of more than 3 anti-hypertensive drugs
- Use of sacubitril/valsartan
- Hemodynamic instability in the first 24 hours until the moment of confirmed diagnosis of COVID-19


Temporarily suspend  
ACEI/ARB treatment for 30 days

Continue to use  
ACEI/ARB treatment


## PRIMARY OUTCOME

Days alive and out of hospital at 30 days

# Primary Outcome: Days Alive and Out of Hospital at 30 Days



# All-Cause Mortality at 30 Days



**Numbers at risk:**

Suspending ACEI/ARB	334	333	331	331	329	328	325
Continuing ACEI/ARB	325	325	322	320	318	316	316